CTLA4 and melanoma: Supplemental Table S1 provides a summary of the number of cases reported in each report, along with the organs involved and the ICI agent used to treat melanoma. Overall, there were 50 GSL cases reported with anti-PD1 as monotherapy, 35 cases with anti-CTLA4 as monotherapy, and 21 cases with anti-PD1 in combination with anti-CTLA4. The most reported GSL type was lymphatic (n = 60), and after that, cutaneous (n = 48), then pulmonary (n = 47), and, lastly, ocular (n = 4) and neurological (n = 3), respectively (Table 2).